Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors


Study Number
479819
Phase
1
Purpose

This study will investigate the safety and tolerability of ADP-A2M4CD8 T-cell therapy in subjects who have the appropriate human leukocyte antigen (HLA) and tumor antigen status and whose synovial sarcoma, myxoid/round cell liposarcoma (MRCLS), melanoma, urothelial, head and neck, ovarian, gastric (stomach), esophagogastric junction (EGJ), non-small cell lung (NSCLC), or esophageal cancer that express the MAGE-A4 protein.

Full Title

ADP-0055-001: A PHASE 1 DOSE ESCALATION STUDY TO ASSESS SAFETY AND EFFICACY OF ADP-A2M4CD8 IN HLA-A2+ SUBJECTS WITH MAGE-A4 POSITIVE TUMORS

ClinicalTrials.Gov ID
NCT04044859

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.